SCHEMBL25801644

SCHEMBL25801644

N#CCc1ccc(C2(C(F)(F)F)CC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 9/20 0.39
L3MBTL1 Q9Y468 1/20 0.36
CACNA1G O43497 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C8 P10632 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2B6 P20813 1/20 0.36
CYP2C19 P33261 1/20 0.36
KCNH2 Q12809 1/20 0.36
CACNA1C Q13936 1/20 0.36
CACNA1I Q9P0X4 1/20 0.36
SIGMAR1 Q99720 1/20 0.34
PTPRC P08575 1/20 0.33
PTPN1 P18031 1/20 0.33
JAK2 O60674 2/20 0.33
JAK1 P23458 2/20 0.33
KMT2A Q03164 1/20 0.32
ENPP2 Q13822 1/20 0.32
TRPA1 O75762 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29268068 0.77 L3MBTL1 (0.40) L3MBTL1PTPRCPTPN1KMT2AENPP2
SCHEMBL516652 0.76 CACNA1H (0.46) CACNA1HCACNA1GCYP3A4CYP2C8CYP2D6
SCHEMBL19302498 0.76 SIGMAR1 (0.39) CACNA1HSIGMAR1NPC1LMNA
SCHEMBL21036238 0.76 PDK2 (0.37) CACNA1HCACNA1GCYP3A4CYP2C8CYP2D6
SCHEMBL21035484 0.76 CACNA1H (0.36) CACNA1HCACNA1GCYP3A4CYP2C8CYP2D6
SCHEMBL24196140 0.76 LOXL2 (0.41) CACNA1HSIGMAR1
SCHEMBL24196137 0.73 PDK2 (0.39) CACNA1HSIGMAR1
SCHEMBL26014791 0.71 PTGS1 (0.40) CYP2C9SIGMAR1LMNA
SCHEMBL25735734 0.71 PDK2 (0.40) CACNA1HSIGMAR1PTPN1
SCHEMBL2154504 0.71 KMT2A (0.47) L3MBTL1KMT2AENPP2NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081511-B3 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2026-03-04 EP disclosed
EP-4442319-A2 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2024-10-09 EP disclosed
EP-4081511-B1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2024-07-31 EP disclosed
EP-3577099-B1 A NOVEL PROCESS FOR THE SYNTHESIS OF 1-ARYL-1-TRIFLUOROMETHYLCYCLOPROPANES IDORSIA PHARMACEUTICALS LTD (CH) 2024-01-24 EP disclosed
EP-3577099-B1 A NOVEL PROCESS FOR THE SYNTHESIS OF 1-ARYL-1-TRIFLUOROMETHYLCYCLOPROPANES IDORSIA PHARMACEUTICALS LTD (CH) 2024-01-24 EP disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed
CN-110234622-B Novel process for the synthesis of 1-aryl-1-trifluoromethyl cyclopropane 爱杜西亚药品有限公司 2023-07-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 CACNA1H 4687/4885L3MBTL1 3425/4885CACNA1G 4600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.